ALK-Abelló A/S

Copenhagen Stock Exchange ALK-B.CO

ALK-Abelló A/S Gross Profit Margin for the year ending December 31, 2023: 62.91%

ALK-Abelló A/S Gross Profit Margin is 62.91% for the year ending December 31, 2023, a 1.69% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

ALK-Abelló A/S Gross Profit Margin for the year ending December 31, 2022 was 61.87%, a 1.12% change year over year.
ALK-Abelló A/S Gross Profit Margin for the year ending December 31, 2021 was 61.18%, a 5.32% change year over year.
ALK-Abelló A/S Gross Profit Margin for the year ending December 31, 2020 was 58.09%, a 0.53% change year over year.
ALK-Abelló A/S Gross Profit Margin for the year ending December 31, 2019 was 57.79%, a 3.16% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Copenhagen Stock Exchange: ALK-B.CO

ALK-Abelló A/S

CEO	Mr. Peter Halling
IPO Date	March 10, 2000
Location	Denmark
Headquarters	Boge Alle 6-8
Employees	2,806
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Key trends

Past 5 years